1338 results
Keyword Dropilton 2% Remove keyword
-
List item
Veterinary medicine European public assessment report (EPAR): Easotic
gentamicin sulfate, hydrocortisone aceponate, miconazole nitrate, Dogs
Date of authorisation: 19/11/2008, Revision: 10, Authorised, Last updated: 18/10/2021ear has been seen in around 2% of dogs. The use of ear preparations … ear has been seen in around 2% of dogs. The use of ear preparations … -
List item
Human medicine European public assessment report (EPAR): Intrarosa
Prasterone, Postmenopause
Date of authorisation: 08/01/2018,
, Revision: 5, Authorised, Last updated: 20/01/2022
compared with about 1% and 2% with placebo. There was also … with Intrarosa compared with 2% and 12% with placebo. In … compared with about 1% and 2% with placebo. There was also … -
List item
Human medicine European public assessment report (EPAR): Biktarvy
bictegravir, emtricitabine, tenofovir alafenamide, fumarate, HIV Infections
Date of authorisation: 21/06/2018,, Revision: 12, Authorised, Last updated: 26/11/2021
went above the threshold in 2% (5 out of 290) of patients … switched to Biktarvy, and in 2% (5 out of 287) of patients … went above the threshold in 2% (5 out of 290) of patients … -
List item
Human medicine European public assessment report (EPAR): Palforzia
defatted powder of Arachis hypogaea L., semen (peanuts), Peanut Hypersensitivity
Date of authorisation: 17/12/2020,, Revision: 2, Authorised, Last updated: 26/11/2021
mild symptoms, compared with 2% of those who received placebo … mild symptoms compared with 2% of those who took placebo … mild symptoms, compared with 2% of those who received placebo … -
List item
Human medicine European public assessment report (EPAR): Braftovi
Encorafenib, Melanoma; Colorectal Neoplasms
Date of authorisation: 19/09/2018,, Revision: 9, Authorised, Last updated: 28/01/2022
treatment, compared with about 2% in those not given Braftovi … -
List item
Human medicine European public assessment report (EPAR): Xofluza
Baloxavir marboxil, Influenza, Human
Date of authorisation: 07/01/2021,, Revision: 1, Authorised, Last updated: 18/01/2022
disease. In this study, around 2% of those who took Xofluza … disease. In this study, around 2% of those who took Xofluza … -
List item
Human medicine European public assessment report (EPAR): Cerdelga
eliglustat, Gaucher Disease
Date of authorisation: 19/01/2015,, 
, Revision: 13, Authorised, Last updated: 11/01/2022
spleen size, compared with a 2% increase in those taking … spleen size, compared with a 2% increase in those taking … -
List item
Human medicine European public assessment report (EPAR): Conbriza
bazedoxifene, Osteoporosis, Postmenopausal
Date of authorisation: 17/04/2009, Revision: 15, Authorised, Last updated: 23/03/2021fractures. After three years, 2% of the patients receiving … -
List item
Human medicine European public assessment report (EPAR): Byfavo (updated)
remimazolam, Conscious Sedation
Date of authorisation: 26/03/2021,, Revision: 1, Authorised, Last updated: 28/04/2022
Byfavo. This compares with 2% (1 out of 60) of patients … Byfavo. This compares with 2% (1 out of 60) of patients … -
List item
Human medicine European public assessment report (EPAR): Nustendi
Bempedoic acid, Ezetimibe, Hypercholesterolemia; Dyslipidemias
Date of authorisation: 27/03/2020,, Revision: 5, Authorised, Last updated: 21/04/2022
and an increase of around 2% with placebo (a dummy treatment … -
List item
Human medicine European public assessment report (EPAR): Nilemdo
Bempedoic acid, Hypercholesterolemia; Dyslipidemias
Date of authorisation: 01/04/2020,, Revision: 6, Authorised, Last updated: 08/04/2022
cholesterol levels of around 2% in both studies in patients … -
List item
Human medicine European public assessment report (EPAR): Skyrizi
Risankizumab, Psoriasis; Arthritis, Psoriatic
Date of authorisation: 26/04/2019,, Revision: 11, Authorised, Last updated: 14/03/2022
PASI scores, compared with 2% of those receiving placebo … PASI scores, compared with 2% of those receiving placebo … -
List item
Human medicine European public assessment report (EPAR): Wegovy
semaglutide, Obesity; Overweight
Date of authorisation: 06/01/2022,, Authorised, Last updated: 10/03/2022
68 weeks compared with a 2% loss of weight in people … 68 weeks compared with a 2% loss of weight in people … -
List item
Human medicine European public assessment report (EPAR): Tavlesse
Fostamatinib disodium, Thrombocytopenia
Date of authorisation: 09/01/2020,, Revision: 4, Authorised, Last updated: 13/01/2022
for 24 weeks compared with 2% of patients receiving placebo … -
List item
Human medicine European public assessment report (EPAR): Aldara
imiquimod, Condylomata Acuminata; Keratosis; Keratosis, Actinic; Carcinoma, Basal Cell
Date of authorisation: 18/09/1998, Revision: 29, Authorised, Last updated: 13/12/2021studies, compared with 15 and 2% in the placebo-treated patients … studies, compared with 15 and 2% in the placebo-treated patients … -
List item
Human medicine European public assessment report (EPAR): Xarelto
rivaroxaban, Arthroplasty, Replacement; Venous Thromboembolism
Date of authorisation: 30/09/2008,, Revision: 36, Authorised, Last updated: 13/12/2021
The second study found that 2% of the patients taking Xarelto … The second study found that 2% of the patients taking Xarelto … -
List item
Human medicine European public assessment report (EPAR): Cholib
fenofibrate, simvastatin, Dyslipidemias
Date of authorisation: 26/08/2013, Revision: 13, Authorised, Last updated: 13/08/2021Cholib compared with around 2% with simvastatin. Another … Cholib compared with around 2% with simvastatin. Another … -
List item
Human medicine European public assessment report (EPAR): Bonviva
ibandronic acid, Osteoporosis, Postmenopausal
Date of authorisation: 23/02/2004, Revision: 28, Authorised, Last updated: 29/03/2021injections, compared with 2% with the daily tablets. What … injections, compared with 2% with the daily tablets … -
List item
Human medicine European public assessment report (EPAR): Evkeeza
Evinacumab, Hypercholesterolemia
Date of authorisation: 17/06/2021,, 
, Authorised, Last updated: 21/04/2021
treatment, compared with about a 2% increase in patients receiving … treatment, compared with about a 2% increase in patients receiving … -
List item
Human medicine European public assessment report (EPAR): Cosentyx (updated)
Secukinumab, Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing
Date of authorisation: 14/01/2015, Revision: 26, Authorised, Last updated: 17/05/2022patients given etanercept and 2% of those given placebo. In … -
List item
Human medicine European public assessment report (EPAR): Dupixent (updated)
dupilumab, Dermatitis, Atopic
Date of authorisation: 26/09/2017,, Revision: 15, Authorised, Last updated: 13/05/2022
weeks compared with around 2% of those given placebo. A … weeks compared with around 2% of those given placebo. A … -
List item
Human medicine European public assessment report (EPAR): Nulojix
belatacept, Graft Rejection; Kidney Transplantation
Date of authorisation: 17/06/2011, Revision: 18, Authorised, Last updated: 20/04/2022Nulojix seen in more than 2% of patients are urinary-tract … -
List item
Human medicine European public assessment report (EPAR): Jentadueto
linagliptin, metformin, Diabetes Mellitus, Type 2
Date of authorisation: 19/07/2012, Revision: 20, Authorised, Last updated: 07/03/2022diarrhoea (seen in around 2% of patients, with a similar … diarrhoea (seen in around 2% of patients, with a similar … -
List item
Human medicine European public assessment report (EPAR): Baraclude
Entecavir, Hepatitis B, Chronic
Date of authorisation: 26/06/2006, Revision: 27, Authorised, Last updated: 11/02/2022their blood compared with 2% of children in the placebo … their blood compared with 2% of children in the placebo … -
List item
Human medicine European public assessment report (EPAR): Prolia
denosumab, Bone Resorption; Osteoporosis, Postmenopausal
Date of authorisation: 26/05/2010, Revision: 25, Authorised, Last updated: 07/09/2021fractures. After three years, 2% of the women receiving Prolia … the first of these studies, 2% of the women receiving Prolia …